XENE

37.0401.38%
SR

Steven R. Gannon

Independent Director

Mr. Steven R. Gannon, also known as Steve, CA, CPA, serves on the board of directors of Ritedose Pharmaceuticals since March 2022. He serves as an Independent Director at Fusion Pharmaceuticals Inc. since January 2020. He had been a Director of Aerogen Limited since 2018 until July 2020. He has served as chairman of the board of directors of Altasciences, a private CRO/CDMO company, since April 2021. He served as the Chief Financial Officer, Senior Vice President of Finance and Treasurer of Axcan Intermediate Holdings Inc., since February 2008. Mr. Gannon served as the Chief Financial Officer of Aptalis MidCo Inc. Mr. Gannon served as Senior Vice President of Finance, Chief Financial Officer and Treasurer of Axcan MidCo Inc. and Axcan Holdings Inc., since February 2008. He served as Chief Financial Officer and Senior Vice President of Aptalis Pharma Canada Inc. (alternately Axcan Pharma Inc.) since April 1, 2006 and served as its Treasurer. Mr. Gannon served as Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Holdings Inc. He served as Principal Accounting Officer of Axcan Intermediate Holdings Inc., since February 2008. He served as the Director of Finance and Administration of the Research Division of Astrazeneca Canada Inc. from 1996 to 1999. He served as the Chief Financial Officer of Mallinckrodt Medical Inc.'s Canadian operations from 1989 to 1995 and served as its Head of Finance and Administration. Mr. Gannon has held a number of senior financial roles in AstraZeneca. He served as Chief Financial Officer and Company Secretary of Medtronic CryoCath LP (alternate name, CryoCath Technologies Inc.) from 1999 to February 24, 2006. Mr. Gannon served as Chief Financial Officer, Senior Vice President of Finance, Principal Accounting Officer and Treasurer of Aptalis Pharma Inc. from February 2008 to February 2014. Mr. Gannon has wealth of financial and operational expertise and close to 30 years of leadership experience in the biopharmaceutical industry. Mr. Gannon has extensive financial experience in corporate growth initiatives including acquisitions, corporate alliance and Partnerships within biotechnology and pharmaceutica companies. He served as Executive Director of Eurand N.V. since January, 2011. He served as Non-Executive Director of Advanced Accelerator Applications S.A. from June 2014 to March 2018. He had been an Independent Director of enGene Holdings Inc. (formerly known as enGene, Inc.) since February 2017 until June 2023. He has been a Director of Axcan Intermediate Holdings Inc., since February 2008 and Xenon Pharmaceuticals Inc. since May 21, 2015. He serves as a Director of Laborie Medical Technologies since September 2016, Axcan MidCo Inc. and Aptalis MidCo Inc. He served as a Director of Aptalis Pharma Inc. since February 2008. He received Bachelor of Commerce in Accounting and Business Systems from the Concordia University in Montreal in 1983 and was awarded his chartered accountant's designation (CA) in 1985. He completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995.

Positions